Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms
Dec. 25, 2025 — Abbott Laboratories heads into the year-end stretch with a rare mix of near-term product momentum and headline-level risk management. Over the past several weeks—culminating in key December announcements—Abbott has secured U.S. FDA approval for a next-generation atrial fibrillation ablation platform, expanded its push into consumer biowearables, navigated an FDA early alert tied to certain FreeStyle Libre sensors, and doubled down on its diagnostics ambitions with a planned ~$23 billion enterprise-value acquisition of Exact Sciences.